No Image Provided

MitoRx Therapeutics

VC Funding

Seed Angel-backed

Healthcare & Biotech Published 25 April 2022

Summary

In a significant market movement during April 2022, MitoRx Therapeutics was the subject of a vc funding. Leading the round was Oxford Technology Management, Longevitytech.fund, Science Angel Syndicate Network, Wren Capital, UK Innovation & Science Seed Fund, The Fink Family Office.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Oxford Technology Management

Lead Investor / Acquirer

Longevitytech.fund

Lead Investor / Acquirer

Science Angel Syndicate Network

Lead Investor / Acquirer

Wren Capital

Lead Investor / Acquirer

UK Innovation

Lead Investor / Acquirer

Science Seed Fund

Lead Investor / Acquirer

The Fink Family Office

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Seed prioritised

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

VC Funding

NuVision Biotherapies

£4,800,000

Mar 2026

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Evaro

£18,000,000

Jan 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.